Research graph
References from Efficacy and Safety of Lorundrostat for Uncontrolled and Treatment-resistant Hypertension: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Local targets link to admitted publications; unresolved targets remain external evidence.
A global view on prevalence of hypertension and human develop index
10.5334/aogh.2591 · 2020 · External reference
Efficacy and safety of aldosterone synthase inhibitors for hypertension: a meta-analysis of randomized controlled trials and systematic review
10.1161/hypertensionaha.124.23962 · 2025 · External reference
The global epidemiology of hypertension
10.1038/s41581-019-0244-2 · 2020 · External reference
Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association
10.1161/hyp.0000000000000084 · 2018 · External reference
Mineralocorticoid receptor antagonists for treatment of hypertension and heart failure
10.14797/mdcj-11-4-235 · 2015 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
10.1136/bmj.n71 · 2021 · External reference
Cochrane handbook for systematic reviews of interventions
2019 · External reference
RoB 2: a revised tool for assessing risk of bias in randomised trials
10.1136/bmj.l4898 · 2019 · External reference
Measuring inconsistency in meta-analyses
10.1136/bmj.327.7414.557 · 2003 · External reference
Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial
10.1001/jama.2023.16029 · 2023 · External reference
Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the launch-HTN randomized clinical trial
10.1001/jama.2025.9413 · 2023 · External reference
Lorundrostat efficacy and safety in patients with uncontrolled hypertension
10.1056/nejmoa2501440 · 2025 · External reference
2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth Joint National Committee (JNC 8)
10.1001/jama.2013.284427 · 2014 · External reference
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in
10.1016/j.jacc.2017.11.006 · 2018 · External reference
How much lowering of blood pressure is required to prevent cardiovascular disease in patients with and without previous cardiovascular disease?
10.1007/s11886-022-01706-4 · 2022 · External reference
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
10.1016/s0140-6736(15)01225-8 · 2016 · External reference
First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor
10.1111/cts.70000 · 2024 · External reference
The emerging role of aldosterone synthase inhibitors in overcoming renin–angiotensin–aldosterone system therapy limitations: a narrative review
10.15420/cfr.2025.09 · 2025 · External reference
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
10.1016/s0140-6736(15)00257-3 · 2015 · External reference
Phase 2 trial of baxdrostat for treatment-resistant hypertension
10.1056/nejmoa2213169 · 2023 · External reference
Aldosterone and aldosterone synthase inhibitors in cardiorenal disease
10.1152/ajpheart.00419.2023 · 2024 · External reference
Emerging therapies for treatment-resistant hypertension: a review of lorundrostat and related selective aldosterone synthase inhibitors
2024 · External reference
Risk of hyperkalemia from renin–angiotensin–aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population
10.1093/ndt/gfz263 · 2021 · External reference
